Suk-Jin Yang

Title: Suk-Jin Yang: Innovator in Cancer Research

Introduction

Suk-Jin Yang is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of cancer research, focusing on innovative methods for diagnosis and treatment. With a total of 2 patents, his work is paving the way for advancements in cancer therapies.

Latest Patents

Yang's latest patents include a composition containing inhibitors of the expression or activity of SH3RF2 for preventing or treating cancer. This invention highlights the role of the SH3RF2 protein, which is known to increase in various cancer tissues. By inhibiting SH3RF2, cancer cells become more sensitive to apoptosis, thereby promoting cell death and reducing tumorigenicity.

Another notable patent is a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in the TTP promoter. This method is particularly effective for diagnosing liver cancer by measuring specific methylation patterns. The invention can also be applied to other cancers and inflammatory diseases characterized by TTP down-regulation.

Career Highlights

Suk-Jin Yang is affiliated with the Korea Research Institute of Bioscience and Biotechnology. His work at this esteemed institution has allowed him to focus on groundbreaking research that addresses critical challenges in cancer treatment.

Collaborations

Yang collaborates with notable colleagues, including Kyung Chan Park and Young Il Yeom, who contribute to his research endeavors. Their combined expertise enhances the potential impact of their innovations in the field of cancer research.

Conclusion

Suk-Jin Yang's contributions to cancer research through his innovative patents demonstrate his commitment to improving diagnosis and treatment options. His work continues to inspire advancements in the medical field, particularly in oncology.